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Background
Despite availability of antiretroviral therapies, a neonatal
vaccine is needed to prevent HIV-1 breast milk transmis-
sion in resource-poor settings. Given the relative immatu-
rity of the infant immune system and the frequent, long-
term exposure to HIV in breast milk, a neonatal HIV vac-
cine must induce quick, strong, and long-lasting anti-HIV
immunity. Our prior studies demonstrated that intramus-
cular immunization with attenuated poxvirus-based SIV
vaccines gave infant macaques partial protection against
oral SIV challenge. We hypothesized that a vaccine vector
that can replicate after oral administration may induce
better mucosal immunity and be more effective.
Objectives
To test the safety, immunogenicity and efficacy of a
recombinant vesicular stomatitis virus (VSV)-SIV gag, pol
env (SIVgpe) prime/modified vaccinia Ankara (MVA)-
SIVgpe boost vaccine regimen in infant rhesus macaques.
Materials and methods
VSV-SIVgpe was orally administered at birth, followed by
intramuscular injection with MVA-SIVgpe at 2 weeks of
age to eight rhesus macaques. All vaccinated and eight
unvaccinated infant macaques were challenged at 4 weeks
of age by a repeated oral low-dose SIVmac251 inoculation
regimen to mimic breast milk exposure. Lymphocyte sub-
sets and SIV-specific T cell responses were assessed by
multiparameter flow cytometry. Antibody levels were
measured by whole SIV-lysate and SIV gp130 env ELISAs.
SIV RNA levels were measured by SIV branched chain
DNA assay.
Results
The VSV/MVA-SIVgpe vaccine elicited SIV-specific plasma
antibodies (IgG and IgA) as well as CD4+ and CD8+T cell
responses in several oral and systemic lymphoid tissues.
Despite the persistence of SIV-specific antibodies and T
cell responses after SIV challenge, these responses were
insufficient to prevent rapid virus dissemination. Plasma
viral RNA levels in most vaccinates were indistinguishable
from controls. Vaccinates with highest SIV gp130 anti-
body levels at the time of oral SIV infection had lowest
viremia. Although few SIV-specific CD8+ T cells were
observed, these cells were activated and had cytotoxic
activity (CD107 expression after in-vitro SIV antigen stim-
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ulation). T cell activation in tonsils was associated with
lower numbers of regulatory T cells in this tissue.
Conclusions
Although this oral + injected SIV vaccine regimen suc-
ceeded in rapidly eliciting virus-specific antibodies and T
cell responses in neonatal macaques, these immune
responses did not limit virus dissemination after oral SIV
inoculation. These data underline some of the challenges
a vaccine must overcome to protect against HIV breast
milk transmission
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